WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 25, 2008--Phase Forward
(NASDAQ: PFWD), a leading provider of data management solutions for
clinical trials and drug safety, today announced that its customer,
Dana-Farber Cancer Institute, is a winner of CIO magazine's 2008 CIO
100 award. The annual award program recognizes organizations around
the world that exemplify the highest level of operational and
strategic excellence in information technology (IT).
Dana-Farber Cancer Institute is the administrative center of the
Dana-Farber/Harvard Cancer Center, the largest cancer center in the
world, with more than 1000 faculty-level scientists performing
clinical, basic and population research.
The Institute won the award for an initiative that involved the
transition from paper-based tracking of clinical trial data to a
software-based system using Phase Forward's InForm(TM) Integrated
Trial Management software. The Institute is a principal teaching
affiliate of the Harvard Medical School and is among the leading
cancer research and care centers in the United States.
"Our IT organization is honored by this recognition of our work in
moving to electronic data capture (EDC) for clinical trials," said
Jeffrey Kessler, chief information officer, Dana-Farber Cancer
Institute. "EDC has reduced the time to access data from as much as
eight weeks to real-time, and decreased the time to resolve queries
from weeks to hours. This translates to more meaningful study
results."
"The CIO 100 honors organizations that have used technology in
innovative ways to generate value to the business," said Abbie
Lundberg, editor in chief of CIO magazine. "Unlike other top lists,
it's not just about who's biggest - it's about who's doing the most
interesting and relevant things."
To date, the Institute has implemented 65 studies using Phase
Forward's InForm software. These studies have been implemented across
seven disease areas and involve more than 2,000 subjects. The
organization's InForm users are located in the U.S., Puerto Rico,
Canada, Australia and New Zealand.
One of the largest EDC projects undertaken to date is a
500-subject, five-year pediatric Acute Lymphoblastic Leukemia (ALL)
study. A total of 50 electronic forms must be completed across eight
visits for each patient in the study, totaling 77,500 data points for
the whole trial. Automating a study of this scope helps to improve
timely access to information, data accuracy and study integrity.
"Dana-Farber has been aggressive and systematic in its migration
from paper to electronic data capture for clinical trials, and the
organization is reaping the benefits of those efforts," said Bob
Weiler, president and CEO of Phase Forward. "We are delighted to see
this recognition for such a deserving team."
For more information on Dana-Farber Cancer Institute, visit
www.dana-farber.org.
About the CIO 100
The recipients of this year's CIO 100 award were selected through
a three-step process. First, companies filled out an online
application form detailing their innovative practices in both business
and IT. Next, a team of judges reviewed the applications in depth,
looking for unique practices and substantial results. Finally, CIO
editors reviewed the judges' recommendations and voted on the final
100.
Complete coverage of the 2008 CIO 100 awards is in the August 15
issue of CIO magazine and available online at www.cio.com. The awards
will be presented at the Broadmoor in Colorado Springs, Colorado, on
August 26 at the conclusion of the tenth annual CIO 100 Symposium and
Awards Ceremony.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers
proven solutions for electronic data capture (InForm(TM)), phase I
clinic automation (LabPas(TM)), clinical data management
(Clintrial(TM)), clinical trials signal detection (CTSD(TM)),
strategic pharmacovigilance (Empirica Signal(TM)) and Signal
Management, adverse event reporting (Empirica Trace(TM)) and applied
data standards (WebSDM(TM)). In addition, the company provides
services in the areas of application implementation, hosting and
validation, data integration, business process optimization, safety
data management and industry standards. Phase Forward's products and
services have been utilized in over 10,000 clinical trials involving
more than 1,000,000 clinical trial study participants at over 280
organizations and regulatory agencies worldwide including:
AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli
Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard
Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk,
PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis,
Schering-Plough Research Institute, Servier, Tibotec and the U.K.
Medicines and Healthcare Products Regulatory Agency. Additional
information about Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things,
the performance and features of Phase Forward's products and services,
future business and operations plans of a Phase Forward customer, and
the ability of Phase Forward's customers to realize benefits from the
use of Phase Forward's products and services. These statements are
neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond Phase Forward's control,
which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the
risks and uncertainties include, among other things, the ability of
Phase Forward's customers to realize benefits from the use of its
products and services, changes in regulatory requirements applicable
to Phase Forward's customers and the manner in which they conduct
business, changes in commonly used industry standards, the possibility
that customers' needs or plans may change over time, and competition.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date hereof. Phase Forward undertakes no obligation to update or
revise the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise. For additional disclosure regarding these and other risks
faced by Phase Forward, see the disclosure contained in Phase
Forward's public filings with the Securities and Exchange Commission
including, without limitation, its most recent Annual Report on Form
10-K.
CONTACT: Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN PR, Inc.
Meghan Locke, 781-672-3147
mlocke@chenpr.com
SOURCE: Phase Forward
